Octapharma receives FDA approval for new Fibryga formulation in AFD
Fibryga is a human plasma-derived fibrinogen concentrate authorised for AFD in the US.
Drug Development
Day One concludes Mersana Therapeutics acquisition
Cellenkos gains FDA orphan drug status for CK0804 to treat myelofibrosis
Zai Lab’s Augtyro receives NMPA approval for solid tumours in China
Takeda and Protagonist seek FDA approval for rusfertide to treat PV
Arrowhead receives Health Canada authorisation for Redemplo to treat FCS
Insilico and Servier announce $888m oncology research agreement
Samsung Bioepis initiates Byooviz commercialisation in Europe
